利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

47 条记录 (耗时 0.026 秒)

    7H-PYRROLOPYRIMIDINE DERIVATIVES
    3.
    发明授权
    7H-PYRROLOPYRIMIDINE DERIVATIVES 有权
    7H-吡咯并嘧啶衍生物

    公开(公告)号：EP1718651B1

    公开(公告)日：2009-04-22

    申请号：EP05715376.9

    申请日：2005-02-17

    申请人： NOVARTIS AG ,  NOVARTIS-PHARMA GMBH

    发明人： CARAVATTI, Giorgio ,  VAUPEL, Andrea

    IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P35/00

    CPC分类号： C07D487/04

    摘要： The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula (I), wherein the symbols and substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives - alone or in combination with one or more other pharmaceutically active compounds - for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour.

    摘要翻译： 本发明涉及式（I）的7H-吡咯并[2,3-d]嘧啶衍生物，其中符号和取代基如说明书中所定义，涉及其制备方法，涉及包含此类衍生物的药物组合物和 使用这些衍生物 - 单独或与一种或多种其它药物活性化合物组合用于制备用于治疗增殖性疾病（例如肿瘤）的药物组合物。

    3-UNSUBSTITUTED N-(ARYL- OR HETEROARVL)-PYRAZOLORI Ý1,5-A¨PYRIMIDINES AS KINASE INHIBITORS
    4.
    发明公开
    3-UNSUBSTITUTED N-(ARYL- OR HETEROARVL)-PYRAZOLORI Ý1,5-A¨PYRIMIDINES AS KINASE INHIBITORS 审中-公开
    3-未取代的N-（芳基 - 或杂芳基） - 吡唑并[1,5-A]嘧啶类作为激酶抑制剂的

    公开(公告)号：EP2004652A1

    公开(公告)日：2008-12-24

    申请号：EP07723893.9

    申请日：2007-04-02

    申请人： NOVARTIS AG ,  NOVARTIS-PHARMA GMBH

    发明人： MASUYA, Keiichi ,  VAUPEL, Andrea ,  IMBACH, Patricia ,  FURET, Pascal

    IPC分类号： C07D487/04 ,  A61K31/519

    CPC分类号： C07D487/04

    摘要： The invention relates to 3-unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidine compounds, their use as kinase inhibitors, new pharmaceutical formulations comprising said compounds, said compounds for use in the diagnostic or therapeutic treatment of warm blooded animals, especially humans, their use in the treatment of diseases or for the manufacture of pharmaceutical formulations useful in the treatment of diseases that respond to modulation of kinase, especially tie-2 kinase, activity, methods of treatment comprising administration of said compounds to a warm-blooded animal, especially a human, and processes for the manufacture of said compounds.

    CYCLIC DIARLY UREAS SUITABLE AS TYROSINE KINASE INHIBITORS
    6.
    发明公开
    CYCLIC DIARLY UREAS SUITABLE AS TYROSINE KINASE INHIBITORS 审中-公开
    作为酪氨酸激酶抑制剂的合适的环脲

    公开(公告)号：EP1807412A1

    公开(公告)日：2007-07-18

    申请号：EP05796941.2

    申请日：2005-09-27

    申请人： Novartis AG ,  Novartis Pharma GmbH

    发明人： BOLD, Guido ,  CARAVATTI, Giorgio ,  FLOERSHEIMER, Andreas ,  FURET, Pascal ,  MANLEY, Paul, W. ,  PISSOT SOLDERMANN, Carole ,  VAUPEL, Andrea

    IPC分类号： C07D401/12 ,  C07D403/12 ,  A61K31/505 ,  A61K31/506 ,  A61P35/00 ,  C07D407/12 ,  C07D417/12 ,  C07D413/12 ,  C07D409/12

    CPC分类号： C07D417/12 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D409/14 ,  C07D417/14

    摘要： The invention relates to novel compounds of Formula (I): wherein p is 1, 2 or 3; n is 0, 1, 2 or 3; mis0,1,2or3; A is CRc, S, NRc or O, where Rc is H or lower alkyl; X, Y and Z are each independently selected fro N or C-R3, wherein at least two of X, Y and Z are N; and each Ra is independently selected from hydrogen and lower-alkyl; each Rb is hydrogen or lower-alkyl; G is a group Ar or represents CN or unsubstituted or substituted lower alkyl; Ar is a saturated or unsaturated cyclic group, which is substituted or unsubstituted and maybe a five or six membered monocyclic or a 8, 9, 10, 11 or 12 membered bicyclic or tricyclic ring and may contain 0, 1, 2 or 3 heteroatoms selected from O, N and S; and wherein the radicals have R1, R2, R3 and R4 have the meanings as defined herein, to salts, esters, N-oxides or prodrugs thereof; and their use in the treatment of protein kinase dependent diseases, their use in the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diaryl urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.